Updated 13/09/2026
The long-chain omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are structural components of cell membranes — concentrated in the brain, retina and cardiac tissue — and precursors of signalling molecules that regulate inflammation resolution. Unlike most nutrients, global intake can be estimated directly from blood: the Omega-3 Index, the percentage of EPA+DHA in red-blood-cell membranes, gives a validated biomarker of long-term status.
The global picture is a deficit map
A landmark global survey of blood omega-3 levels published in Progress in Lipid Research mapped EPA+DHA status across 54 countries and found that most of the world’s population sits in the low or very low range, with an Omega-3 Index at or below 4% across large regions — against the 8% level associated in cohort studies with the lowest cardiovascular risk. Analyses of global dietary data similarly conclude that roughly three-quarters of the world’s population consumes less EPA/DHA than typical intake recommendations of 250–500 mg per day — the “76% shortfall” figure that has become a standard reference point in nutrition-policy discussions. Only a handful of populations with high oily-fish consumption — Japan, South Korea, Scandinavia, Arctic communities — reach adequate status through diet alone.
What drives the shortfall
Three structural forces explain it. Falling fish consumption: outside coastal food cultures, oily fish (salmon, sardine, mackerel, herring) has been displaced by poultry and processed meats that contain minimal EPA/DHA. The omega-6 flood: industrial seed oils raised omega-6 linoleic acid intake several-fold over the twentieth century; because omega-6 and omega-3 fatty acids compete for the same conversion enzymes, high omega-6 intake further suppresses the already-inefficient conversion of plant-based ALA into EPA and DHA — typically well under 10% for EPA and only a few percent for DHA. The ALA misunderstanding: flaxseed and walnuts supply ALA, but relying on conversion leaves EPA/DHA status largely unchanged, which is why blood surveys show vegetarians and vegans among the lowest-status groups despite adequate total omega-3 intake on paper.
Closing the gap
The intervention options are direct: two servings of oily fish weekly, or supplementation with fish-oil or algal-oil EPA/DHA — the algae route providing the same preformed molecules fish themselves obtain from the marine food chain, relevant for vegetarians and for anyone prioritising a low-contaminant, sustainable source. Because EPA and DHA are highly oxidation-prone, product freshness (verified peroxide values) matters as much as dose.
The Omega-3 Index, properly explained
Most nutrients are judged by intake questionnaires; omega-3 status can be judged by membranes. The Omega-3 Index measures EPA+DHA as a percentage of total fatty acids in red-blood-cell membranes — a four-month integrated record, analogous to how HbA1c integrates glucose. The interpretive bands from the cardiovascular cohort literature: ≤4% high-risk zone (typical for the Americas and much of Europe), 4–8% intermediate, ≥8% target (typical of Japan, where population cardiac event rates helped define the goal). Because the biomarker exists, omega-3 is one of the few supplements where “is it working?” has a laboratory answer: re-test after 3–4 months and titrate.
A century of dietary drift: how the ratio flipped
Estimated omega-6:omega-3 intake ratios in ancestral and traditional diets cluster somewhere near 1–4:1. Modern Western patterns run at 15–20:1. Two industrial shifts did it: seed-oil refining made linoleic-acid-rich oils (soybean, corn, sunflower) the cheapest calories in the food system, embedding them in processed food; and livestock moved from pasture (omega-3-containing forage) to grain feeding, stripping omega-3 from meat, eggs and dairy. The result is a food environment where achieving 250 mg EPA+DHA daily without deliberate intent — fish twice a week or supplementation — is statistically unusual, which is precisely what the 76% shortfall figure quantifies.
Populations where the gap matters most
Pregnancy: the fetal brain accretes DHA fastest in the third trimester; Cochrane analysis links maternal omega-3 supplementation to reduced early-preterm birth, making this the highest-stakes deficiency window. Vegans and vegetarians: blood surveys place them lowest of all measured groups; algal EPA/DHA is the only effective correction. Older adults: intake tends to fall with appetite while cardiovascular relevance rises. High-omega-6 consumers: heavy processed-food patterns both displace omega-3 sources and competitively suppress what little conversion from plant ALA exists.
What policy is doing about it
Governments have noticed. Dietary guidelines on several continents now specify oily-fish servings or EPA/DHA milligrams; EFSA’s authorised claims created a legal vocabulary for products delivering ≥250 mg/day; some countries fortify staples or permit omega-3 nutrition claims to steer reformulation; and the biomarker itself is entering preventive-medicine panels. The policy consensus is unusually aligned with the supplement aisle here: this is a documented population-scale gap with a cheap, measurable fix — the main open questions are dose and form for specific outcomes, not whether the gap exists.
The clinical bottom line
Omega-3 inadequacy is not a fringe deficiency; blood-level data make it one of the most widespread nutritional gaps measured, affecting an estimated three in four people globally. It is also among the most directly correctable — through oily fish or preformed EPA/DHA supplementation, not through ALA arithmetic.
Primary sources
- Stark KD, et al. Global survey of the omega-3 fatty acids EPA and DHA in the blood stream of healthy adults. Prog Lipid Res. 2016
- Micha R, et al. / Global Burden of Disease dietary analyses on seafood omega-3 intake
- NIH Office of Dietary Supplements: Omega-3 Fatty Acids — Health Professional Fact Sheet
- WHO: Healthy diet fact sheet
🗺️ Find certified Georgian healthcare providers: sheniekimi.ge — Georgia Health Map · 998 clinics · 6,600+ doctors · 2,296 pharmacies
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
